[Trends in global burden due to visceral leishmaniasis from 1990 to 2021 and projections up to 2035].

Q3 Medicine
G Yang, A He, Y Li, S Lü, M Chen, L Tian, Q Liu, L Duan, Y Lu, J Yang, S Li, X Zhou, J Wang, S Zhang
{"title":"[Trends in global burden due to visceral leishmaniasis from 1990 to 2021 and projections up to 2035].","authors":"G Yang, A He, Y Li, S Lü, M Chen, L Tian, Q Liu, L Duan, Y Lu, J Yang, S Li, X Zhou, J Wang, S Zhang","doi":"10.16250/j.32.1915.2024251","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the global burden of visceral leishmaniasis (VL) from 1990 to 2021 and predict the trends in the burden of VL from 2022 to 2035, so as to provide insights into global VL prevention and control.</p><p><strong>Methods: </strong>The global age-standardized incidence, prevalence, mortality and disability-adjusted life years (DALYs) rates of VL and their 95% uncertainty intervals (<i>UI</i>) were captured from the Global Burden of Disease Study 2021 (GBD 2021) data resources. The trends in the global burden of VL were evaluated with average annual percent change (AAPC) and 95% confidence interval (<i>CI</i>) from 1990 to 2021, and gender-, age-, country-, geographical area- and socio-demographic index (SDI)-stratified burdens of VL were analyzed. The trends in the global burden of VL were projected with a Bayesian age-period-cohort (BAPC) model from 2022 to 2035, and the associations of age-standardized incidence, prevalence, mortality, and DALYs rates of VL with SDI levels were examined with a smoothing spline model.</p><p><strong>Results: </strong>The global age-standardized incidence [AAPC = -0.25%, 95% <i>CI</i>: (-0.25%, -0.24%)], prevalence [AAPC = -0.06%, 95% <i>CI</i>: (-0.06%, -0.06%)], mortality [AAPC = -0.25%, 95% <i>CI</i>: (-0.25%, -0.24%)] and DALYs rates of VL [AAPC = -2.38%, 95% <i>CI</i>: (-2.44%, -2.33%)] all appeared a tendency towards a decline from 1990 to 2021, and the highest age-standardized incidence [2.55/10<sup>5</sup>, 95% <i>UI</i>: (1.49/10<sup>5</sup>, 4.07/10<sup>5</sup>)], prevalence [0.64/10<sup>5</sup>, 95% <i>UI</i>: (0.37/10<sup>5</sup>, 1.02/10<sup>5</sup>)], mortality [0.51/10<sup>5</sup>, 95% <i>UI</i>: (0, 1.80/10<sup>5</sup>)] and DALYs rates of VL [33.81/10<sup>5</sup>, 95% <i>UI</i>: (0.06/10<sup>5</sup>, 124.09/10<sup>5</sup>)] were seen in tropical Latin America in 2021. The global age-standardized incidence and prevalence of VL were both higher among men [0.57/10<sup>5</sup>, 95% <i>UI</i>: (0.45/10<sup>5</sup>, 0.72/10<sup>5</sup>); 0.14/10<sup>5</sup>, 95% <i>UI</i>: (0.11/10<sup>5</sup>, 0.18/10<sup>5</sup>)] than among women [0.27/10<sup>5</sup>, 95% <i>UI</i>: (0.21/10<sup>5</sup>, 0.33/10<sup>5</sup>); 0.06/10<sup>5</sup>, 95% <i>UI</i>: (0.05/10<sup>5</sup>, 0.08/10<sup>5</sup>)], and the highest mortality of VL was found among children under 5 years of age [0.24/10<sup>5</sup>, 95% <i>UI</i>: (0.08/10<sup>5</sup>, 0.66/10<sup>5</sup>)]. The age-standardized incidence (<i>r</i> = -0.483, <i>P</i> < 0.001), prevalence (<i>r</i> = -0.483, <i>P</i> < 0.001), mortality (<i>r</i> = -0.511, <i>P</i> < 0.001) and DALYs rates of VL (<i>r</i> = -0.514, <i>P</i> < 0.001) correlated negatively with SDI levels from 1990 to 2021. In addition, the global burden of VL was projected with the BAPC model to appear a tendency towards a decline from 2022 to 2035, and the age-standardized incidence, prevalence, mortality and DALYs rates were projected to be reduced to 0.11/10<sup>5</sup>, 0.03/10<sup>5</sup>, 0.02/10<sup>5</sup> and 1.44/10<sup>5</sup> in 2035, respectively.</p><p><strong>Conclusions: </strong>Although the global burden of VL appeared an overall tendency towards a decline from 1990 to 2021, the burden of VL showed a tendency towards a rise in Central Asia and western sub-Saharan African areas. The age-standardized incidence and prevalence rates of VL were relatively higher among men, and the age-standardized mortality of VL was relatively higher among children under 5 years of age. The global burden of VL was projected to continue to decline from 2022 to 2035.</p>","PeriodicalId":38874,"journal":{"name":"中国血吸虫病防治杂志","volume":"37 1","pages":"35-43"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国血吸虫病防治杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.16250/j.32.1915.2024251","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To investigate the global burden of visceral leishmaniasis (VL) from 1990 to 2021 and predict the trends in the burden of VL from 2022 to 2035, so as to provide insights into global VL prevention and control.

Methods: The global age-standardized incidence, prevalence, mortality and disability-adjusted life years (DALYs) rates of VL and their 95% uncertainty intervals (UI) were captured from the Global Burden of Disease Study 2021 (GBD 2021) data resources. The trends in the global burden of VL were evaluated with average annual percent change (AAPC) and 95% confidence interval (CI) from 1990 to 2021, and gender-, age-, country-, geographical area- and socio-demographic index (SDI)-stratified burdens of VL were analyzed. The trends in the global burden of VL were projected with a Bayesian age-period-cohort (BAPC) model from 2022 to 2035, and the associations of age-standardized incidence, prevalence, mortality, and DALYs rates of VL with SDI levels were examined with a smoothing spline model.

Results: The global age-standardized incidence [AAPC = -0.25%, 95% CI: (-0.25%, -0.24%)], prevalence [AAPC = -0.06%, 95% CI: (-0.06%, -0.06%)], mortality [AAPC = -0.25%, 95% CI: (-0.25%, -0.24%)] and DALYs rates of VL [AAPC = -2.38%, 95% CI: (-2.44%, -2.33%)] all appeared a tendency towards a decline from 1990 to 2021, and the highest age-standardized incidence [2.55/105, 95% UI: (1.49/105, 4.07/105)], prevalence [0.64/105, 95% UI: (0.37/105, 1.02/105)], mortality [0.51/105, 95% UI: (0, 1.80/105)] and DALYs rates of VL [33.81/105, 95% UI: (0.06/105, 124.09/105)] were seen in tropical Latin America in 2021. The global age-standardized incidence and prevalence of VL were both higher among men [0.57/105, 95% UI: (0.45/105, 0.72/105); 0.14/105, 95% UI: (0.11/105, 0.18/105)] than among women [0.27/105, 95% UI: (0.21/105, 0.33/105); 0.06/105, 95% UI: (0.05/105, 0.08/105)], and the highest mortality of VL was found among children under 5 years of age [0.24/105, 95% UI: (0.08/105, 0.66/105)]. The age-standardized incidence (r = -0.483, P < 0.001), prevalence (r = -0.483, P < 0.001), mortality (r = -0.511, P < 0.001) and DALYs rates of VL (r = -0.514, P < 0.001) correlated negatively with SDI levels from 1990 to 2021. In addition, the global burden of VL was projected with the BAPC model to appear a tendency towards a decline from 2022 to 2035, and the age-standardized incidence, prevalence, mortality and DALYs rates were projected to be reduced to 0.11/105, 0.03/105, 0.02/105 and 1.44/105 in 2035, respectively.

Conclusions: Although the global burden of VL appeared an overall tendency towards a decline from 1990 to 2021, the burden of VL showed a tendency towards a rise in Central Asia and western sub-Saharan African areas. The age-standardized incidence and prevalence rates of VL were relatively higher among men, and the age-standardized mortality of VL was relatively higher among children under 5 years of age. The global burden of VL was projected to continue to decline from 2022 to 2035.

[1990年至2021年内脏利什曼病全球负担趋势及2035年预测]。
目的:了解1990 - 2021年全球内脏利什曼病(VL)负担情况,预测2022 - 2035年内脏利什曼病负担趋势,为全球内脏利什曼病防控提供依据。方法:从全球疾病负担研究2021 (GBD 2021)数据资源中获取VL的全球年龄标准化发病率、患病率、死亡率和残疾调整生命年(DALYs)率及其95%不确定区间(UI)。以1990年至2021年的平均年百分比变化(AAPC)和95%置信区间(CI)评估全球VL负担的趋势,并分析按性别、年龄、国家、地理区域和社会人口指数(SDI)分层的VL负担。采用贝叶斯年龄-时期-队列(BAPC)模型预测2022年至2035年全球VL负担的趋势,并采用平滑样条模型检验年龄标准化VL发病率、患病率、死亡率和DALYs率与SDI水平的关系。结果:全球年龄标准化发病率[AAPC = -0.25%, 95% CI:(-0.25%, -0.24%)]、患病率[AAPC = -0.06%, 95% CI:(-0.06%, -0.06%)]、死亡率[AAPC = -0.25%, 95% CI:(-0.25%, -0.24%)]和VL的DALYs率[AAPC = -2.38%, 95% CI:(-2.44%, -2.33%)]从1990年到2021年均呈下降趋势,其中年龄标准化发病率最高[2.55/105,95% UI:(1.49/105, 4.07/105)]、患病率[0.64/105,95% UI:(0.37/105, 1.02/105)]、死亡率[0.51/105,95% UI: 95%];(0,1.80 /105)]和2021年拉丁美洲热带地区VL的DALYs率[33.81/105,95% UI:(0.06/105, 124.09/105)]。全球年龄标准化VL发病率和患病率在男性中均较高[0.57/105,95% UI: (0.45/105, 0.72/105);0.14/105, 95% UI:(0.11/105, 0.18/105)]高于女性[0.27/105,95% UI: (0.21/105, 0.33/105)];其中5岁以下儿童VL死亡率最高[0.24/105,95% UI:(0.08/105, 0.66/105)]。年龄标准化发病率(r = -0.483, P < 0.001)、患病率(r = -0.483, P < 0.001)、死亡率(r = -0.511, P < 0.001)和VL DALYs率(r = -0.514, P < 0.001)与1990 - 2021年SDI水平呈负相关。此外,BAPC模型预测2022 - 2035年全球VL负担呈下降趋势,2035年年龄标准化发病率、患病率、死亡率和DALYs分别降至0.11/105、0.03/105、0.02/105和1.44/105。结论:尽管1990 - 2021年全球VL负担总体呈下降趋势,但中亚和撒哈拉以南非洲西部地区VL负担呈上升趋势。男性VL的年龄标准化发病率和患病率较高,5岁以下儿童VL的年龄标准化死亡率较高。预计从2022年到2035年,全球VL负担将继续下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中国血吸虫病防治杂志
中国血吸虫病防治杂志 Medicine-Medicine (all)
CiteScore
1.30
自引率
0.00%
发文量
7021
期刊介绍: Chinese Journal of Schistosomiasis Control (ISSN: 1005-6661, CN: 32-1374/R), founded in 1989, is a technical and scientific journal under the supervision of Jiangsu Provincial Health Commission and organised by Jiangsu Institute of Schistosomiasis Control. It is a scientific and technical journal under the supervision of Jiangsu Provincial Health Commission and sponsored by Jiangsu Institute of Schistosomiasis Prevention and Control. The journal carries out the policy of prevention-oriented, control-oriented, nationwide and grassroots, adheres to the tenet of scientific research service for the prevention and treatment of schistosomiasis and other parasitic diseases, and mainly publishes academic papers reflecting the latest achievements and dynamics of prevention and treatment of schistosomiasis and other parasitic diseases, scientific research and management, etc. The main columns are Guest Contributions, Experts‘ Commentary, Experts’ Perspectives, Experts' Forums, Theses, Prevention and Treatment Research, Experimental Research, The main columns include Guest Contributions, Expert Commentaries, Expert Perspectives, Expert Forums, Treatises, Prevention and Control Studies, Experimental Studies, Clinical Studies, Prevention and Control Experiences, Prevention and Control Management, Reviews, Case Reports, and Information, etc. The journal is a useful reference material for the professional and technical personnel of schistosomiasis and parasitic disease prevention and control research, management workers, and teachers and students of medical schools.    The journal is now included in important domestic databases, such as Chinese Core List (8th edition), China Science Citation Database (Core Edition), China Science and Technology Core Journals (Statistical Source Journals), and is also included in MEDLINE/PubMed, Scopus, EBSCO, Chemical Abstract, Embase, Zoological Record, JSTChina, Ulrichsweb, Western Pacific Region Index Medicus, CABI and other international authoritative databases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信